Curium's $8B buyout and new FDA approval reshape Lantheus
Curium agrees to acquire Lantheus for up to $8 billion Curium will pay $102.50 per share in cash plus up to $12 more if sales targets are met, a 14.9% premium. This puts a firm floor under the stock and is the main reason it trades near the offer price.
The buyout is the single biggest force driving LNTH's price and future value.
FDA approves Tauklarify for tau PET imaging The FDA approved Tauklarify, a new imaging agent for Alzheimer's tau pathology. This adds a new product to Lantheus's portfolio and could support the contingent value rights tied to future sales.
A new FDA approval is a fresh positive catalyst that can affect the buyout's contingent payments.
FDA rejects LNTH-2501 due to third-party facility issues The FDA issued a Complete Response Letter for LNTH-2501, a PET diagnostic for neuroendocrine tumors, because of unresolved manufacturing issues at a partner's facility. This delays a potential product but does not question the drug's data.
This is a fresh regulatory setback that could weigh on sentiment and future growth prospects.